Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Effect of irinotecan on urinary Δ9- tetrahydrocannabinol elimination in Wistar rats (CROSBI ID 677011)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Brčić Karačonji, Irena ; Miljanić, Alena ; Jurič, Andreja ; Brajenović, Nataša ; Micek, Vedran ; Neuberg, Marijana ; Kozina, Goran ; Lucić Vrdoljak, Ana ; Mikolić, Anja Effect of irinotecan on urinary Δ9- tetrahydrocannabinol elimination in Wistar rats // The abstracts of The 2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis2019) / Häuser, Winfried ; Brill, Silviu (ur.). Basel: S. Karger AG, Basel, 2019. str. 3-4 doi: 10.1159/000500623

Podaci o odgovornosti

Brčić Karačonji, Irena ; Miljanić, Alena ; Jurič, Andreja ; Brajenović, Nataša ; Micek, Vedran ; Neuberg, Marijana ; Kozina, Goran ; Lucić Vrdoljak, Ana ; Mikolić, Anja

engleski

Effect of irinotecan on urinary Δ9- tetrahydrocannabinol elimination in Wistar rats

Background: Due to growing public interest in the antitumor potential of Δ9- tetrahydrocannabinol (THC) and its possible role as an agent for alleviating side-effects of chemotherapy with irinotecan (IRI), some oncology patients have begun to reach for highly concentrated THC preparations. Since IRI, THC and their metabolites are subjected to glucuronic acid conjugation via the same enzyme (UGT1A1), co-administered THC could reduce IRI metabolism and clearance of its metabolites (particularly SN-38), leading to enhanced toxicity. Objective: The aim of the study was to compare the urinary elimination of free (non- conjugated) THC and its metabolites [11-hydroxy- Δ9-THC (THC- OH) and 11-nor-9-carboxy-Δ9-THC (THC-COOH)] in IRI+THC treated rats with rats treated only with THC. Methods: Male Wistar rats (N = 5 per group) were administered a combination of a single dose of IRI (100 mg/kg b.w, i.p.) and THC (7 mg/kg b.w., p.o.) or THC only. Urine samples were collected during the first 24 h after the treatment. THC, THC-OH and THC-COOH concentrations were determined by gas chromatography-mass spectrometry. Results: Enhanced urinary THC-OH and THC-COOH excretion was noted in rats administered combined treatment compared to single THC treatment. Conclusion: Increased non-conjugated THC metabolite urinary concentrations in combined treatment might point to the competition of THC and IRI for the same enzyme in phase II metabolism. Further studies are needed to elucidate the increase of the free fraction of THC metabolites in the concomitant use of IRI and THC.

Tetrahydrocannabinol ; irinotecan ; urinary elimination ; GC-MS ; rat

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

3-4.

2019.

nije evidentirano

objavljeno

10.1159/000500623

Podaci o matičnoj publikaciji

The abstracts of The 2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis2019)

Häuser, Winfried ; Brill, Silviu

Basel: S. Karger AG, Basel

2504-3889

Podaci o skupu

2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis2019)

poster

23.05.2019-24.05.2019

Barcelona, Španjolska

Povezanost rada

Kemija, Temeljne medicinske znanosti

Poveznice